[Passive Tau immunotherapy for prevention of Tau pathology progression].
F. Hoffmann-La Roche Ltd., Preclinical Research Neuroscience, PCDMR, Grenzacherstrasse, CH-4070 Basel, Suisse.
Laurence
L
Ozmen
F. Hoffmann-La Roche Ltd., Preclinical Research Neuroscience, PCDMR, Grenzacherstrasse, CH-4070 Basel, Suisse.
Ludovic
L
Collin
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use; D000918:Antibody Specificity; D004195:Disease Models, Animal; D018450:Disease Progression; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007116:Immunization, Passive; D008247:Lysosomes / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D016874:Neurofibrillary Tangles / Q000737:chemistry; D009474:Neurons / Q000473:pathology; D010768:Phosphoserine / Q000737:chemistry; D066263:Protein Aggregation, Pathological / Q000209:etiology / Q000517:prevention & control; D024801:Tauopathies / Q000517:prevention & control / Q000628:therapy*; D016875:tau Proteins / Q000172:deficiency / Q000378:metabolism / Q000502:physiology*
D000911:Antibodies, Monoclonal; C054369:MAPT protein, human; C558298:Mapt protein, mouse; D016875:tau Proteins; D010768:Phosphoserine